Autorinnen und Autoren des Paul-Ehrlich-Instituts sind durch Fettdruck kenntlich gemacht. Wenn Online-Abstracts oder Volltexte zu den Publikationen verfügbar sind, so sind diese verlinkt.
Ebenig A, Lange MV, Gellhorn Serra M, Kupke A, Plesker R, Qu B, Brown RJP, Maier TJ, Mühlebach MD (2025): Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19.
NPJ Vaccines 10: 51.
Text
Qu B, Miskey C, Gömer A, Kleinert RDV, Calvo Ibanez S, Eberle R, Ebenig A, Postmus D, Nocke MK, Herrmann M, Itotia TK, Herrmann ST, Heinen N, Höck S, Hastert FD, von Rhein C, Schürmann C, Li X, van Zandbergen G, Widera M, Ciesek S, Schnierle BS, Tarr AW, Steinmann E, Goffinet C, Pfaender S, Krijnse Locker J, Mühlebach MD, Todt D, Brown RJP (2024): TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology and drives convergent virus evolution.
Proc Natl Acad Sci U S A 121: e2407437121.
Text
Hörner C, Fiedler AH, Bodmer BS, Walz L, Scheuplein VA, Hutzler S, Matrosovich MN, von Messling V, Mühlebach MD (2023): A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9.
NPJ Vaccines 8: 46.
Text
Pennitz P, Goekeri C, Trimpert J, Wyler E, Ebenig A, Weissfuss C, Mühlebach MD, Witzenrath M, Nouailles G (2023): Protocol to dissociate healthy and infected murine- and hamster-derived lung tissue for single-cell transcriptome analysis.
STAR Protoc 4: 101957.
Text
Auste A, Mühlebach MD (2022): Concentrating all helper protein functions on a single entity allows rescue of recombinant measles virus by transfection of just two plasmids.
J Gen Virol 103: 001815.
Text
Ebenig A, Lange MV, Mühlebach MD (2022): Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.
NPJ Vaccines 7: 119.
Online-Abstract
Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, Gömer A, Postmus D, Gogesch P, Niles M, Plesker R, Miskey C, Gellhorn Serra M, Breithaupt A, Hörner C, Kruip C, Ehmann R, Ivics Z, Waibler Z, Pfaender S, Wyler E, Landthaler M, Kupke A, Nouailles G, Goffinet C, Brown RJP, Mühlebach MD (2022): Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization.
Cell Rep 40: 111214.
Online-Abstract
Henss L, Auste A, Schürmann C, Schmidt C, von Rhein C, Mühlebach MD, Schnierle BS (2021): The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
J Gen Virol 102: 001574.
Text
Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, Eberle J, Ehrhardt A, Engeland CE, Fechner H, Geletneky K, Goepfert K, Holm PS, Kochanek S, Kreppel F, Krutzke L, Kühnel F, Lang KS, Marchini A, Moehler M, Mühlebach MD, Naumann U, Nawroth R, Nüesch J, Rommelaere J, Lauer UM, Ungerechts G (2021): Virotherapy in Germany - Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
Viruses 13: 1420.
Text
Hörner C, Schürmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon KH, Scholz T, Herrmann M, Schnierle B, Baric RS, Mühlebach MD (2020): A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine.
Proc Natl Acad Sci USA 117: 32657-32666.
Text
Mühlebach MD (2020): Measles virus in cancer therapy.
Curr Opin Virol 41: 85-97.
Online-Abstract
Turonova B, Sikora M, Schürmann C, Hagen WJH, Welsch S, Blanc FEC, Bülow von S, Gecht M, Bagola K, Hörner C, van Zandbergen G, Mosalaganti S, Schwarz A, Covino R, Mühlebach MD, Hummer G, Krijnse Locker J, Beck M (2020): In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges.
Science 370: 203-208.
Text
Hanauer JRH, Koch V, Lauer UM, Mühlebach MD (2019): High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency.
Mol Ther Oncolytics 15: 186-200.
Online-Abstract
Mühlebach MD, Cattaneo R: Development of Entry-Targeted Oncolytic Measles Viruses.
In: Engeland C (Hrsg.), Oncolytic Viruses. Methods in Molecular Biology (Vol. 2058). New York, NY: Humana, 2019. S. 51-75, ISBN 978-1-4939-9794-7
Nürnberger C, Bodmer BS, Fiedler AH, Gabriel G, Mühlebach MD (2019): A measles virus-based vaccine candidate mediates protection against Zika virus in an 1 allogenic mouse pregnancy model.
J Virol 93: e01485-18.
Online-Abstract
Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G (2019): Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.
Mol Ther Oncolytics 12: 147-161.
Text
Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer S, Mühlebach MD (2018): Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
Virology 521: 99-107.
Online-Abstract
Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z (2018): Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro.
Mol Immunol 101: 19-28.
Online-Abstract
Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD (2017): Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
Sci Rep 7: 16892.
Text
Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ (2017): Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.
Front Oncol 7: Article 127.
Text
Mühlebach MD, Hutzler S (2017): Development of Recombinant Measles Virus-Based Vaccines.
Methods Mole Biol 1581: 151-168.
Online-Abstract
Mühlebach MD (2017): Vaccine platform recombinant measles virus.
Virus Genes 53: 733-740.
Online-Abstract
Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM (2017): Virotherapy Research in Germany: From Engineering to Translation.
Hum Gene Ther 28: 800-819.
Online-Abstract
Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S (2016): Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.
Virology 489: 1-11.
Online-Abstract
Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD (2016): Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.
Mol Ther Oncolytics 3: 16003.
Text
Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C (2016): APOBEC4 Enhances the Replication of HIV-1.
PLOS ONE 11: e0155422.
Text
Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Shams Eldin H, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD (2015): A highly immunogenic and protective MERS-Coronavirus vaccine based on recombinant MV vaccine platform.
J Virol 89: 11654-11667.
Online-Abstract
Scheuplein VA, Seifried J, Malczyk AH, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD (2015): High secretion of interferons by human plasmacytoid dendritic cells upon recognition of MERS-CoV.
J Virol 89: 3859-3869.
Online-Abstract
Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD (2015): Lentiviral protein transfer vectors are an efficient vaccine-platform inducing strong antigen-specific cytotoxic T cell response.
J Virol 89: 9044-9060.
Online-Abstract
Weiss K, Gerstenberger J, Salzig D, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2015): Oncolytic measles viruses produced at different scales under serum-free conditions.
Eng Life Sci 15: 425-436.
Online-Abstract
Mühlebach MD, Hutzler S: Oncolytic viruses.
Britten CM, Kreiter S, Diken M, Rammensee HG (Hrsg.), Cancer Immunotherapy Meets Oncology. Cham: Springer International Publishing, 2014 ISBN 9783319051031
Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Völker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 1-10.
Online-Abstract
Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Muehlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 865-874.
Online-Abstract
Friedrich K, Hanauer JRH, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD (2013): DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.
Mol Ther 21: 849-859.
Online-Abstract
Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ (2013): Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.
Hum Gene Ther Clin Dev 24: 11-22.
Online-Abstract
Weiss K, Salzig D, Röder Y, Gerstenberger J, Mühlebach MD, Cichutek K, Pörtner R, Czermak P (2013): Influence of Process Conditions on Measles Virus Stability.
Am J Biochem Biotechnol 9: 243-254.
Online-Abstract
Weiss K, Salzig D, Mühlebach MD, Cichutek K, Pförtner R, Czermak P (2012): Key Parameters of Measles Virus Production for Oncolytic Virotherapy.
Am J Biochem Biotechnol 8: 81-98.
Online-Abstract
Mühlebach MD, Buchholz CJ, Götz KB (2011): Das Masernvirus im Fokus - von wirksamen und sicheren Impfstoffen über Krebstherapie bis hin zum Gentransfer.
Bulletin zur Arzneimittelsicherheit 2: 20-23.
Text
Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VHJ, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray Jr PB, Cichutek K, von Messling V, Lopez M, Cattaneo R (2011): Adherens junction protein nectin-4 (PVRL4) is the epithelial receptor for measles virus.
Nature 480: 530-533.
Text
Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ (2011): DARPins: an efficient targeting domain for lentiviral vectors.
Mol Ther 19: 686-693.
Online-Abstract
Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuss H, Hamdorf M, Schweitzer M, Cichutek K, Flory E (2011): Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease.
Retrovirology 8: 14.
Online-Abstract
Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M (2010): Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.
J Gene Med 12: 446-452.
Online-Abstract
Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KMO, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ (2010): Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Cancer Res 70: 7620-7629.
Online-Abstract
Mühlebach MD, Schüle S, Gerlach N, Schweizer M, Buchholz CJ, Hohenadl C, Cichutek K: Gammaretroviral and Lentiviral Vectors for Gene Delivery.
In: Kurth R, Bannert N (Hrsg.), Retroviruses: Molecular Biology, Genomics and Pathogenesis. Norfolk: Caister Academic Press, 2010. 347-370 ISBN 9781904455554
Buchholz CJ, Mühlebach MD, Cichutek K (2009): Lentiviral vectors with measles virus glycoproteins – dream team for gene transfer?.
Trends Biotechnol 27: 259-265.
Online-Abstract
Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ (2009): Pseudotyping lentiviral vectors with the wildtype measles virus glycoproteins improves titer and selectivity.
Gene Ther 16: 700-705.
Online-Abstract
Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ (2008): Targeted cell entry of lentiviral vectors.
Mol Ther 16: 1427-1436.
Online-Abstract
Mühlebach MD, Leonard VHJ, Cattaneo R (2008): The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion efficiency.
J Virol 82: 11437-45.
Online-Abstract
Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M (2007): Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.
Virology 364: 330-341.
Online-Abstract
Mühlebach MD, Wolfrum N, Schüle S, Tschulena U, Sanzenbacher R, Flory E, Cichutek K, Schweizer M (2005): Stable Transduction of Primary Human Monocytes by Simian Lentiviral Vector PBj.
Mol Ther 12: 1206-1216.
Steidl S, Schüle S, Mühlebach MD, Stitz J, Boller K, Cichutek K, Schweizer M (2004): Genetic engineering of onco/lentivirus hybrids results in formation of infectious particles but not of replication-competent viruses.
J Gen Virol 85: 665-678.
Online-Abstract
Mühlebach MD, Schmitt I, Steidl S, Stitz J, Schweizer M, Blankenstein T, Cichutek K, Uckert W (2003): Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.
J Mol Med 81: 801-810.
Online-Abstract
Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K (2001): A Novel Lentivirus vector derived from apathogenic simian immunodeficiency virus.
Virology 291: 191-197.
Online-Abstract
